Eficacia de ustekinumab en el tratamiento de la psoriasis moderada-grave
Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis
Servicio de Dermatología. Hospital Universitario Reina Sofía. Córdoba. España
Read
5013
Timeswas read the article
2083
Total PDF
2930
Total HTML
Share statistics
array:23 [ "pii" => "S0001731012700042" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70004-2" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70004" "copyright" => "Academia Española de Dermatología y Venereología" "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:16-24" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1703 "formatos" => array:2 [ "HTML" => 1283 "PDF" => 420 ] ] "itemSiguiente" => array:18 [ "pii" => "S0001731012700054" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70005-4" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70005" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:25-30" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1163 "formatos" => array:2 [ "HTML" => 621 "PDF" => 542 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Ustekinumab. Análisis de efectos adversos infecciosos" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "25" "paginaFinal" => "30" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Ustekinumab. Analysis of Rates of Infection" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Herranz-Pinto, E. Sendagorta" "autores" => array:2 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Herranz-Pinto" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Sendagorta" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700054?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700054/v1_201304241722/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731012700030" "issn" => "00017310" "doi" => "10.1016/S0001-7310(12)70003-0" "estado" => "S300" "fechaPublicacion" => "2012-10-01" "aid" => "70003" "copyright" => "Academia Española de Dermatología y Venereología" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2012;103 Supl 2:7-15" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2317 "formatos" => array:2 [ "HTML" => 1150 "PDF" => 1167 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Mecanismo de acción de ustekinumab y su relevancia en la patogénesis de la psoriasis. Impacto en el sistema inmune" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "7" "paginaFinal" => "15" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Mechanism of Action of Ustekinumab and its Relevance in the Pathogenesisof Psoriasis. Impact on the Immune System" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.M. Carrascosa" "autores" => array:1 [ 0 => array:2 [ "nombre" => "J.M." "apellidos" => "Carrascosa" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700030?idApp=UINPBA000044" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700030/v1_201304241722/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Eficacia de ustekinumab en el tratamiento de la psoriasis moderada-grave" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "16" "paginaFinal" => "24" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "R. Jiménez-Puya, J.C. Moreno" "autores" => array:2 [ 0 => array:4 [ "nombre" => "R." "apellidos" => "Jiménez-Puya" "email" => array:1 [ 0 => "rjjimenez@uco.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "J.C." "apellidos" => "Moreno" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Dermatología. Hospital Universitario Reina Sofía. Córdoba. España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Efficacy of Ustekinumab in the Treatment of Moderate-Severe Psoriasis" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec85086" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "IL-12" 3 => "IL-23" 4 => "Subunidad p40" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec85085" "palabras" => array:5 [ 0 => "Ustekinumab" 1 => "Psoriasis" 2 => "IL 12" 3 => "IL-23" 4 => "p40 subunit" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">El avance en el conocimiento de la fisiopatología de la psoriasis ha permitido producir nuevas terapias más eficaces y seguras en el manejo de la enfermedad, primero con el bloqueo del factor de necrosis tumoral α y, posteriormente, de forma más específica el de la vía interleucina 12/23. Las interleucinas 12 y 23 desempeñan un importante rol en la cascada inmunitaria de la psoriasis, compartiendo la subunidad proteica p40 que permite bloquear ambas citocinas, actuando de forma más concreta en la producción de la placa inflamatoria.</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La eficacia de ustekinumab se ha contrastado en diversos ensayos clínicos en fase III (PHOENIX 1 y 2), y su desarrollo clínico abarca el mayor número de pacientes estudiado con un agente biológico, siendo también el único en compararse de forma <span class="elsevierStyleItalic">head to head</span> con etanercept, un agente bloqueante del factor de necrosis tumoral α (estudio ACCEPT).</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Improved understanding of the pathophysiology of psoriasis has led to the development of biologic agents that offer improved safety and efficacy in the treatment of this disease. TNF inhibitors were the first biologics to be added to the therapeutic arsenal, and these were followed by agents that selectively block IL-12 and IL-23, two cytokines that play an important role in the immune cascade that leads to psoriasis. By targeting the p40 subunit shared by these cytokines, ustekinumab blocks the activity of IL 12/23, thereby reducing skin inflammation.</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">The efficacy of ustekinumab has been analyzed in phase III clinical trials (PHOENIX 1 and 2) and its clinical development program was the largest ever for a biologic agent. Ustekinumab has also been compared to the TNF inhibitor etanercept in the first-ever head-to-head comparison of biologic agents in psoriasis (the ACCEPT psoriasis trial).</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Psoriasis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M.P. Schön" 1 => "W.H. Boehncke" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMra041320" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "352" "paginaInicial" => "1899" "paginaFinal" => "1912" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15872205" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0091674910015666" "estado" => "S300" "issn" => "00916749" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New IL-12-family members: IL-23 and IL-17 cytokines with divergent functions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "C.A. Hunter" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/nri1648" "Revista" => array:6 [ "tituloSerie" => "Nat Rev Immunol" "fecha" => "2005" "volumen" => "5" "paginaInicial" => "521" "paginaFinal" => "531" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15999093" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ustekinumab: a new option in psoriasis therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A.L. Chien" 1 => "J.T. Elder" 2 => "C.N. Ellis" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2009" "volumen" => "69" "paginaInicial" => "1141" "paginaFinal" => "1152" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19537833" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 1 study investigators" "etal" => true "autores" => array:6 [ 0 => "C.L. Leonardi" 1 => "A.B. Kimball" 2 => "K.A. Papp" 3 => "N. Yeilding" 4 => "C. Guzzo" 5 => "Y. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60725-4" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1665" "paginaFinal" => "1674" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486739" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0091674910019445" "estado" => "S300" "issn" => "00916749" ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2)" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "PHOENIX 2 study investigators" "etal" => true "autores" => array:6 [ 0 => "K.A. Papp" 1 => "R.G. Langley" 2 => "M. Lebwohl" 3 => "G.G. Krueger" 4 => "P. Szapary" 5 => "N. Yeilding" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60726-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "1675" "paginaFinal" => "1684" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18486740" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Lebwohl" 1 => "N. Yeilding" 2 => "P. Szapary" 3 => "Y. Wang" 4 => "S. Li" 5 => "Y. Zhu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2009.11.012" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2010" "volumen" => "63" "paginaInicial" => "571" "paginaFinal" => "579" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20599293" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ustekunimab SPC [consultado 11/02/2009]. Disponible en: <a id="ir0015" class="elsevierStyleInterRef" href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/stelara/H-958-PI-en.pdf">http://www.emea.europa.eu/humandocs/PDFs/EPAR/stelara/H-958-PI-en.pdf</a>." ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Rich P, Feldman S, Vender R, Ortonne JP, Rustin M, et al. Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis. Poster P040 presentado en el Congress of the Psoriasis InternationalNetwork. Paríes, Jul 2010." ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Kimball A, Goffe B, Bissonnette R, Yeilding N, Li S, et al. Efficacy of ustekinumab is sustained through 3 years of treatment for patients with moderate-to-severe psoriasis maintained on q12 week dosing based on body weight. Poster presentado en el Congress of the Psoriasis International Network; París, Francia. Jul 2010 Julio. Póster P044." ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Gordon K, Lambert J, Gratton D, Baker D, Matheson R, et al. Sustained efficacy of ustekinumab for the treatment of moderate to severe psoriasis in initial responders continuing with maintenance therapy through year 3. Poster presentado en el Congress of the Psoriasis International Network; París, Francia. Jul 2010. Póster P046." ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ghislain PD, Poulin Y, Wasel N, Sofen H, Yeilding N, et al. Maintenance of long-term efficacy of ustekinumab through year 3 for patients with moderate-to-severe psoriasis. Poster presentado en el 19.° Congreso de la European Academy of Dermatology and Venereology; Gothenburg, Sweden. Oct 2010. Poster P589." ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Sobell J, Hamilton T, Reich K, Ho V, Toth D, et al. Improved clinical response following a third dose of ustekinumab in psoriasis patients not achieving pasi75 at week 16: results from the phoenix 1 and phoenix 2 trials. Póster presentado en el Congress of the Psoriasis International Network; París. Jul 2010. Póster P045." ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Griffiths C, Strober B, Van der Kerkhof PCM, Ho V, Guzzo C, et al. A phase 3, multicenter, randomized study comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. Póster presentado en el Congreso de la EADV 2008. Paris. Póster P1336." ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Responses to ustekinumab in the anti-TNF agent-naïve vs. anti- TNF agent-exposed patients with psoriasis vulgaris" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Clemmensen" 1 => "M. Spon" 2 => "L. Skov" 3 => "C. Zachariae" 4 => "R. Gniadecki" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1468-3083.2010.03914.x" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol" "fecha" => "2011" "volumen" => "25" "paginaInicial" => "1037" "paginaFinal" => "1040" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21108668" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Jiménez Puya R, Salido Vallejo R, Gómez García F, Casas Asunción E, Vélez García-Nieto A, Moreno Giménez JC. Efficacy and safety of ustekinumab in the treatment of moderate and severe psoriatic patients: an open-label study. Póster presentado en el Summer Meeting de la AAD 2010, Chicago. Póster 2330." ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00017310/00000103000000S2/v1_201304241722/S0001731012700042/v1_201304241722/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00017310/00000103000000S2/v1_201304241722/S0001731012700042/v1_201304241722/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731012700042?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 8 | 12 | 20 |
| 2024 October | 43 | 37 | 80 |
| 2024 September | 55 | 28 | 83 |
| 2024 August | 51 | 55 | 106 |
| 2024 July | 72 | 27 | 99 |
| 2024 June | 58 | 51 | 109 |
| 2024 May | 49 | 31 | 80 |
| 2024 April | 44 | 36 | 80 |
| 2024 March | 45 | 37 | 82 |
| 2024 February | 30 | 33 | 63 |
| 2024 January | 23 | 23 | 46 |
| 2023 December | 19 | 14 | 33 |
| 2023 November | 23 | 26 | 49 |
| 2023 October | 13 | 9 | 22 |
| 2023 September | 37 | 35 | 72 |
| 2023 August | 23 | 23 | 46 |
| 2023 July | 33 | 30 | 63 |
| 2023 June | 27 | 28 | 55 |
| 2023 May | 10 | 8 | 18 |
| 2023 April | 18 | 13 | 31 |
| 2023 March | 19 | 20 | 39 |
| 2023 February | 15 | 18 | 33 |
| 2023 January | 17 | 29 | 46 |
| 2022 December | 30 | 26 | 56 |
| 2022 November | 31 | 28 | 59 |
| 2022 October | 35 | 27 | 62 |
| 2022 September | 21 | 30 | 51 |
| 2022 August | 42 | 37 | 79 |
| 2022 July | 33 | 35 | 68 |
| 2022 June | 20 | 25 | 45 |
| 2022 May | 36 | 43 | 79 |
| 2022 April | 31 | 29 | 60 |
| 2022 March | 35 | 50 | 85 |
| 2022 February | 17 | 26 | 43 |
| 2022 January | 20 | 41 | 61 |
| 2021 December | 29 | 49 | 78 |
| 2021 November | 25 | 47 | 72 |
| 2021 October | 34 | 49 | 83 |
| 2021 September | 22 | 39 | 61 |
| 2021 August | 37 | 34 | 71 |
| 2021 July | 24 | 31 | 55 |
| 2021 June | 21 | 41 | 62 |
| 2021 May | 23 | 46 | 69 |
| 2021 April | 52 | 55 | 107 |
| 2021 March | 30 | 38 | 68 |
| 2021 February | 34 | 24 | 58 |
| 2021 January | 17 | 16 | 33 |
| 2020 December | 23 | 19 | 42 |
| 2020 November | 29 | 15 | 44 |
| 2020 October | 17 | 14 | 31 |
| 2020 September | 16 | 8 | 24 |
| 2020 August | 28 | 12 | 40 |
| 2020 July | 22 | 17 | 39 |
| 2020 June | 17 | 22 | 39 |
| 2020 May | 22 | 21 | 43 |
| 2020 April | 19 | 21 | 40 |
| 2020 March | 22 | 24 | 46 |
| 2020 February | 1 | 3 | 4 |
| 2019 December | 0 | 1 | 1 |
| 2019 November | 0 | 2 | 2 |
| 2019 October | 0 | 1 | 1 |
| 2019 September | 0 | 3 | 3 |
| 2019 July | 0 | 2 | 2 |
| 2019 June | 0 | 3 | 3 |
| 2019 May | 1 | 12 | 13 |
| 2019 February | 0 | 1 | 1 |
| 2019 January | 0 | 1 | 1 |
| 2018 December | 0 | 3 | 3 |
| 2018 November | 0 | 7 | 7 |
| 2018 October | 0 | 1 | 1 |
| 2018 September | 1 | 0 | 1 |
| 2018 March | 2 | 0 | 2 |
| 2018 February | 54 | 5 | 59 |
| 2018 January | 42 | 3 | 45 |
| 2017 December | 40 | 10 | 50 |
| 2017 November | 35 | 4 | 39 |
| 2017 October | 30 | 6 | 36 |
| 2017 September | 22 | 5 | 27 |
| 2017 August | 48 | 6 | 54 |
| 2017 July | 43 | 6 | 49 |
| 2017 June | 56 | 6 | 62 |
| 2017 May | 40 | 11 | 51 |
| 2017 April | 51 | 8 | 59 |
| 2017 March | 26 | 16 | 42 |
| 2017 February | 33 | 5 | 38 |
| 2017 January | 35 | 8 | 43 |
| 2016 December | 35 | 6 | 41 |
| 2016 November | 54 | 7 | 61 |
| 2016 October | 54 | 8 | 62 |
| 2016 September | 53 | 10 | 63 |
| 2016 August | 60 | 13 | 73 |
| 2016 July | 31 | 7 | 38 |
| 2016 May | 0 | 11 | 11 |
| 2016 April | 1 | 0 | 1 |
| 2016 February | 0 | 3 | 3 |
| 2016 January | 0 | 18 | 18 |
| 2015 December | 0 | 18 | 18 |
| 2015 November | 8 | 12 | 20 |
| 2015 October | 2 | 7 | 9 |
| 2015 September | 10 | 13 | 23 |
| 2015 August | 2 | 7 | 9 |
| 2015 July | 37 | 3 | 40 |
| 2015 June | 26 | 4 | 30 |
| 2015 May | 65 | 28 | 93 |
| 2015 April | 38 | 14 | 52 |
| 2015 March | 39 | 9 | 48 |
| 2015 February | 38 | 12 | 50 |
| 2015 January | 31 | 14 | 45 |
| 2014 December | 60 | 8 | 68 |
| 2014 November | 32 | 12 | 44 |
| 2014 October | 35 | 25 | 60 |
| 2014 August | 1 | 0 | 1 |
| 2014 May | 1 | 0 | 1 |
| 2014 January | 2 | 2 | 4 |
| 2013 October | 1 | 0 | 1 |
| 2013 September | 0 | 1 | 1 |
| 2013 June | 5 | 5 | 10 |
| 2013 May | 1 | 1 | 2 |
| 2013 April | 1 | 1 | 2 |
| 2013 March | 1 | 1 | 2 |
| 2013 February | 0 | 1 | 1 |
| 2013 January | 0 | 1 | 1 |
Show all
